March 22, 2024Open Access

Nonpathogenic E. coli engineered to surface display cytokines as a new platform for immunotherapy

View Full Paper

Ask AI

Bookmark

Authors

RRRizwan RomeeHarvard University SYShaobo YangNortheastern University MSMichal ShefferDana-Farber Cancer Institute

Discussion

Member takes

Implication

Preclinical study shows engineered E. coli displaying IL-18 stimulates anti-tumor immunity in murine cancer models, highlighting a potent delivery platform for solid tumor immunotherapy.

Key Points

Nonpathogenic Escherichia coli engineered to display decoy-resistant IL18 cytokines induces robust immune responses and cures mice bearing colorectal carcinoma and melanoma.
Display of human DR18 on bacteria enhances CAR NK cell trafficking into tumors, activating TNFα signaling via NFκB and improving survival in resistant xenograft mesothelioma.
In vivo mouse models show bacterial tumor tropism and durable immunologic memory, supporting further clinical evaluation of this bacterial immunotherapy platform in solid tumors.

Cite This Study

Romee et al. (2024) studied this question.

synapsesocial.com/papers/68e72babb6db6435876a5c42 https://doi.org/10.21203/rs.3.rs-4031911/v1

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study shows engineered E. coli displaying IL-18 stimulates anti-tumor immunity in murine cancer models, highlighting a potent delivery platform for solid tumor immunotherapy.

Nonpathogenic E. coli engineered to surface display cytokines as a new platform for immunotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Nonpathogenic E. coli engineered to surface display cytokines as a new platform for immunotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider